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ARTICLE
Downregulating carnitine palmitoyl transferase 1
affects disease progression in the SOD1 G93A
mouse model of ALS
Michael Sloth Trabjerg 1, Dennis Christian Andersen1, Pam Huntjens1, Kirsten Egelund Oklinski1, Luise Bolther1,
Jonas Laugård Hald1, Amalie Elton Baisgaard1, Kasper Mørk1, Nikolaj Warming1, Ulla Bismark Kullab1,
Lona John Kroese2, Colin Eliot Jason Pritchard2, Ivo Johan Huijbers 3 & John Dirk Vestergaard Nieland 1✉
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease characterized by death of
motor neurons. The etiology and pathogenesis remains elusive despite decades of intensive
research. Herein, we report that dysregulated metabolism plays a central role in the SOD1
G93A mouse model mimicking ALS. Specifically, we report that the activity of carnitine
palmitoyl transferase 1 (CPT1) lipid metabolism is associated with disease progression.
Downregulation of CPT1 activity by pharmacological and genetic methods results in ameli-
oration of disease symptoms, inflammation, oxidative stress and mitochondrial function,
whereas upregulation by high-fat diet or corticosterone results in a more aggressive disease
progression. Finally, we show that downregulating CPT1 shifts the gut microbiota commu-
nities towards a protective phenotype in SOD1 G93A mice. These findings reveal that
metabolism, and specifically CPT1 lipid metabolism plays a central role in the SOD1 G93A
mouse model and shows that CPT1 might be a therapeutic target in ALS.
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Amyotrophic lateral sclerosis (ALS) is a progressive neuro-degenerative disease affecting both the central nervoussystem (CNS) and periphery1. It is characterized by
degeneration of upper- and lower-motor neurons resulting in
death caused by respiratory failure within 3 years in many cases1.
The incidence of ALS is 1–2 cases per year per 100,000 people with
a cumulative lifetime risk of 1:4002. ALS exists in a sporadic- and a
familial form, which accounts for 10% of all ALS cases1. The male
to female ratio is ~2:1 for the sporadic form and 1:1 in the familiar
form1. The first mutation to be associated with the familiar form of
ALS was in the SOD1 gene coding for the protein superoxide
dismutase 1 (SOD1)3. Mutations in SOD1 are responsible for ~20%
of all familial cases and 1–3% of all sporadic cases1. The most
prevalent mutation in SOD1 is the glycine to alanine conversion at
the 93rd codon resulting in a toxic gain-of-function4. However, in
the last decade, several genes have been associated with a risk of
ALS, and the disease has a broad heterogeneity with several clinical
phenotypes5. The etiology of ALS remains elusive, but mechanisms
causing the motor neuron degeneration in ALS include deposition
of protein- and RNA aggregates, oxidative stress, endoplasmic
reticulum stress, glutamate excitotoxicity, mitochondrial dysfunc-
tion, and neuroinflammation1,6. At the moment, there is only two
FDA approved drugs, both of them with little- to no therapeutic
effect on survival of the patients5,7. Interestingly, enhanced lipid
metabolism and decreased glucose metabolism has been observed
in ALS patients and animal models and have been associated with
disease progression8. Dupuis and colleagues9 investigated whether
energy homeostasis is defective in two transgenic ALS lines, the
SOD1 G86R and SOD1 G93A mice, and found several indications
of dysregulated metabolism. At day 105, the lipid concentration
was significant lower in the transgenic SOD1 G93A mice com-
pared to healthy control animals. Dodge et al.10 examined whether
SOD1 G93A mice undergo metabolic changes during disease. They
showed that transgenic SOD1 G93A mice present several changes
indicative of altered lipid metabolism, such as reduced circulating
triglyceride levels and reduced fat mass. One of the key molecules
in lipid metabolism is carnitine palmitoyl transferase 1 (CPT1),
which facilitates the transport of medium-long chained fatty acids
across the outer mitochondrial membrane to undergo β-oxidation
to produce acetyl-coA. CPT1 exists in three isoforms; CPT1A,
which is located in most of the body, CPT1B, which is solely
located in the muscles, and adipose tissue and CPT1C, which is
only present in the CNS but is associated with the endoplasmic
reticulum11. Upregulated lipid metabolism is essential for the
survival of immune cells, and it enhances multiple pathogenic
processes, including inflammation, oxidative stress, and mito-
chondrial dysfunction12–14. Furthermore, production of acyl-CoA
through upregulated β-oxidation results in a negative feedback to
pyruvate, which results in decreased glucose metabolism, leading to
a vicious cycle disrupting the homeostasis15. CPT1A and CPT1B
have been found to be upregulated in the SOD1 mouse model16–19.
Further, human populations, which have a significant reduction in
CPT1A activity, have been found to have a decreased prevalence of
CNS diseases such as multiple sclerosis and ALS20,21. We have
previously shown that blocking of CPT1 by an irreversible CPT1
antagonist or by genetic inhibition show clinical-relevant effects in
in vivo models of neurodegenerative diseases, diminishes inflam-
mation, demyelination oxidative stress and increases mitochon-
drial biogenesis20,22–24. Further, Timmers et al.25 have shown that
a CPT1 antagonist upregulates glucose metabolism and insulin
sensitivity. Recently it was shown that tissue-specific knock-out of
Cpt1b in mouse muscles results in increased oxidative capacity,
glucose metabolism, and insulin sensitivity26.
Based on reported findings of the dysregulated metabolism in
ALS patients and in vivo models of ALS, we tested the hypothesis
that blocking or downregulation of lipid metabolism through
CPT1 modulation affected disease progression in the SOD1 G93A
mouse model of ALS. Herein, we report that pharmaceutical and
genetic inhibition of CPT1 is able to delay disease progression in
the SOD1 G93A model. Further, we report that environmental
dysregulation of metabolism through saturated animal-based
high-fat diet (HFD) and corticosterone results in a more
aggressive disease progression. We also report that modulation of
CPT1 results in alternations of the serum levels of glucose and
lipids, inflammatory, oxidative stress, neuronal, glial and meta-
bolic markers in the spinal cord and inflammatory, oxidative
stress, metabolic and denervation markers in the tibialis anterior
muscles. Finally, we report that modulation of CPT1 activity
results in changes in the fecal gut microbiota, which is consistent
with the increased recognition of the possible role of dysregulated
microbiota in ALS and other neurodegenerative diseases. Alto-
gether, these results suggest that the upregulated CPT1 lipid
metabolism plays a critical role in the pathogenesis of the SOD1
G93A familiar form of ALS and that downregulation of CPT1
might be a potential target to restore the hyperactive metabolism.
Results
CPT1 antagonist delays disease onset and alleviate clinical
symptoms in SOD1 G93A mice. The SOD1 G93A (over-
expressing human SOD1 G93A) mouse display progressive defi-
cits in fine and gross motor function, as well as some degree of
cognitive impairment4,27. The SOD1 G93A gene mutation was the
first gene linked to ALS, providing an epidemiological foundation
for the SOD1 G93A mouse model3. Defects in motor coordina-
tion become evident from the age of 70 days27. Several studies
have indicated that the metabolism is dysregulated in the per-
iphery and CNS in the SOD1 G93A model from early disease
stages and onward9,16,19,28. Based on this, we tested the effect of
blocking CPT1, which previously has been shown to shift the
metabolism from lipid- to glucose metabolism and show clinical-
relevant effects in a pilot study24,25.
Female SOD1 G93A mice (SOD1) and their female wildtype
littermates (Wt) were randomized into treatment with a CPT1
antagonist (etomoxir) (SOD1+ E, Wt+E) or placebo (SOD1+ P,
Wt+P) from day 70 (Fig. 1a). Etomoxir targets both CPT1A and
CPT1B by antagonistic mechanism in the periphery and CNS and
is indicated to cross the BBB based on functional analysis and
chemical structure. Motor function was evaluated weekly from
day 70 by rotarod29, hangwire30, grip strength24 test and
neurological score31, as previously validated in this model.
Further, visuospatial memory and spontaneous activity were
evaluated using the y-maze test- and cylinder test. The y-maze
test has recently been validated in the SOD1 G93A model27. The
spontaneous activity cylinder test has not been conducted in the
SOD1 G93A model previously according to the authors’ knowl-
edge. The test has, however, been validated in several other mouse
models as a measure of sensorimotor function- and spontaneous
activity32. SOD1 G93A mice develop tremor in their hind legs as
one of their characteristics30. Interestingly, the SOD1+ P mice
(median onset= 89 days) developed tremor significantly earlier
(p= <0.0001) compared to the SOD1+ E mice (median onset=
106.5 days), indicating that etomoxir delayed disease onset
(Fig. 1b). This was consistent with significantly lower neurological
score from day 91 and throughout the experiment for the
SOD1+ E mice (Fig. 1c). The rotarod test did not find any
significant differences between the SOD1 groups. However, the
SOD1+ P had a significantly lower latency to fall compared to
the Wt group throughout the experiment, which was not the case
for the SOD1+ E group (Fig. 1d). Interestingly, the SOD1+ E
mice had a significant increase in their normalized grip strength
following treatment with the irreversible CPT1 antagonist and
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had a significant higher grip strength compared to SOD1+ P
mice for 9 weeks (Fig. 1e). SOD1+ E mice had a significant
higher latency to fall on the hangwire test for several weeks
(Fig. 1f). SOD1 G93A mice lose weight during their disease
progression, which was also the case in this study (Fig. 1g).
SOD1+ P had a significant weight loss compared to their
wildtype littermates, which was calculated as the weight ratio day
147/day 70 (Fig. 1h). The cylinder test showed that SOD1+ E
mice had a significant higher number of rears at day 100 and day
130 compared to SOD1+ P mice (Fig. 1i) indicating a better
sensorimotor function- and higher activity. SOD1+ P mice had a
significantly lower spontaneous alternation percentage (SAP) in
the y-maze at day 100 compared to Wt+P (Fig. 1j), indicating a
loss of visuospatial memory. Strikingly, the SOD1+ E mice had a
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significant higher SAP at both day 100- and day 130 compared to
SOD1+ P (Fig. 1j). As ALS is characterized by decreased survival
this is also a relevant parameter in the SOD1 G93A mouse model,
but we did not find any significant difference (p= 0.12) between
the SOD1+ P (median survival= 150 days) and SOD1+ E
groups (only 1 mouse reached a neurological score of 4, and,
therefore, no median survival can be calculated) (Fig. 1k). Overall,
the behavioral data indicated that downregulation of CPT1 was
able to delay disease progression in the SOD1 G93A mouse model
based on clinical-relevant effects. This was in accordance with
two other studies testing the effects of downregulating CPT1 from
day 70 and until day 130 (Fig. 1l, m) and from day 100
(Supplementary Fig. 1). Sexual dimorphism have been reported to
oppose a problem in the B6SJL-Tg(SOD1*G93A)1Gur/J mouse
model but not in the B6.Cg-Tg(SOD1*G93A)1Gur/J model33,
which was used in this study. Accordingly, we did not find any
difference in clinical-relevant phenotype between male and
female SOD1 mice at day 140 nor survival (Supplementary
Fig. 2).
CPT1 antagonist restore glucose metabolism and attenuates
disease processes in the spinal cord and tibialis anterior mus-
cles in SOD1 G93A mice. A higher level of low-density lipo-
protein (LDL) and LDL/high-density lipoprotein (HDL) ratio has
been associated with an increased risk of ALS34–37. However,
discrepancies between studies assessing the effect of LDL, HDL
and LDL/HDL ratio on survival in ALS exists38,39. To assess
whether blocking CPT1 in SOD1 G93A mice affected lipid
metabolism, serum levels of glucose, LDL and HDL were eval-
uated following termination of the animal experiment. SOD1+ P
had a significant higher serum level of glucose compared to their
wildtype littermates, which was not the case for SOD1+ E mice
(Fig. 2a). This could indicate that etomoxir restored metabolism
towards glucose utilization in the SOD1 mice. Interestingly, sig-
nificant differences in the serum levels of LDL, HDL and LDL/
HDL ratio were found between the SOD1+ E and SOD1+ P
mice (Fig. 2b–d). SOD1+ E mice displayed a significantly lower
s-LDL, higher s-HDL and lower s-LDL/HDL ratio, which is
consistent with a physiological lipid phenotype for the C57Bl/6J
strain and in accordance with healthy controls compared to ALS
patients37,40.
Based on the clinical-relevant effects by downregulation of
CPT1 by etomoxir presented in Fig. 1, we speculated, which
disease mechanisms were affected. A hallmark of disease in the
SOD1 G93A model is death of motor neurons in the spinal cord.
Therefore, we evaluated the serum level of neurofilament light-
chain (NF-L), as this has been validated as a biomarker for
neurodegenerative diseases, disease progression, survival and
death of large myelinated neurons, including motor neurons41.
Wt mice had significantly lower serum levels of NF-L compared
to both SOD1 treatment groups (Fig. 2e), indicating death of large
myelinated neurons in the SOD1 G93A mouse model, as
expected. However, the SOD1+ E mice had significantly lower
serum levels of NF-L compared to SOD1+ P mice, which could
indicate possible protective effects on large myelinated neurons
following etomoxir treatment. In addition, we evaluated the
protein level of choline o-acetyltransferase (ChAT) in the spinal
cord to assess motor neuron death4. SOD1+ P mice had
significantly lower levels of ChAT compared to Wt+P, which
was not the case for SOD1+ E mice (Fig. 2f). This indicates that
the death of motor neurons in the SOD1+ E group possibly was
ameliorated by etomoxir.
Another hallmark of disease progression in ALS is reactive
microglia and inflammation in the CNS6. Therefore, we evaluated
the level of CX3CR1 in the spinal cord, as a marker of reactive
microglia and activated macrophages. SOD1+ P mice had a
tendency towards a significant higher level compared to Wt mice
(Fig. 2g), which indicated increased pathological microglial
reaction in the spinal cord of SOD1+ P mice compared to
SOD1+ E mice. Next, we evaluated the levels of the anti-
inflammatory cytokine interleukin (IL)-10 (Fig. 2h) and pro-
inflammatory cytokines IL-1β (Fig. 2i) and tumor necrosis factor
alpha (TNF-α; Fig. 2j) in the spinal cord. Both SOD1+ P and
SOD1+ E mice had significantly decreased levels of IL-10
compared to Wt but etomoxir treated SOD1 mice had
significantly lower levels of the pro-inflammatory cytokines
compared to SOD1+ P mice (Fig. 2h–j). This indicates that
etomoxir modulates the inflammatory profile in the CNS and
periphery.
Subsequently, we evaluated the gene expression profile of
metabolic, glial, inflammatory and oxidative stress markers in the
spinal cord. Overall, SOD1+ P mice had lower expression of,
Cpt1c, Pcg1α, Glut4, Apoe, Chat, Mbp and Nrf2 and increased
expression of Iba1, Casp1 and IL-17α (Fig. 2k–m), indicating
pathological processes such as mitochondrial dysfunction, down-
regulated glucose metabolism, death of motor neurons, disrup-
tion of myelin, oxidative stress and inflammation. Interestingly,
the CPT1 antagonist resulted in gene expressions associated with
amelioration of disease such as increased mitochondrial biogen-
esis, glucose metabolism, myelination, oxidative stress defense
and diminished inflammation (Fig. 2k–m). Knockout of Cpt1c
has been shown to cause detrimental effects on CNS function in
mice, implying that the downregulation of Cpt1c in the SOD1+ P
group could play a role for disease progression42,43. Pcg1α was
upregulated by etomoxir and has been shown to be protective in
the SOD1 G93A mouse model44. Interestingly, etomoxir resulted
Fig. 1 Downregulating CPT1 by etomoxir ameliorate clinical symptoms and delays disease progression in the SOD1 G93A mouse model. a Experimental
setup, mice were randomized into treatment with etomoxir or placebo at approximately day 70 (baseline) and tested weekly until day. b Time point for
onset of disease defined as visible tremor in hindlimbs (n= 11–15), log-rank survival analysis. c Neuroscore was assessed once a week. Mean neuroscore ±
SEM (n= 8–10). d Rotarod test was performed once a week. Mean latency to fall ± SEM (n= 4–7). e Grip strength was measured once a week from day
70. Data are presented as mean normalized strength ± SEM (n= 4–10). f Hangwire test was performed once a week. Mean latency to fall of the grid ± SEM
(n= 4–10). g Mean body weight expressed in grams ± SEM (n= 4–10). h Mean body weight ratio at day 147 compared to baseline ± SEM (n= 4–10), one-
way ANOVA with Tukey post hoc test. i Cylinder test was performed at day 70, 100, and 130. Mean ratio rears between day 100, 130, and baseline ± SEM
(n= 4–10). j Y-maze test was conducted at day 70, 100, and 130. Mean spontaneous alternation percentage ± SEM (n= 4–10). k Survival was defined as
neuroscore below 4, (n= 8–10), log-rank survival analysis. If nothing else is noted, data was analyzed using repeated measure two-way ANOVA followed
by Tukey post hoc test. l Mean neuroscore for SOD1 mice treated from day 70 and until day 130 ± SEM (n= 4–7). m Mean normalized grip strength for
SOD1 mice treated from day 70 and until day 130 ± SEM (n= 4–7). Data are representative of three experiments. Repeated measure two-way ANOVA
with Tukey post hoc test was performed if nothing else is stated. *Significant differences between SOD1+ E and SOD1+ P, #significant differences
between SOD1 G93A+ P and Wt, $significant differences between SOD1+ E and Wt. *p≤ 0.05; **p≤ 0.01; #p≤ 0.05; ##p≤ 0.01; $p≤ 0.05; $$p≤ 0.01
WT=wild-type, SOD1= SOD1 G93A genotype, E= etomoxir, P= placebo. Mouse figure used in experimental setup figures were obtained from; https://
smart.servier.com/ and used according to the Creative Commons Attribution 3.0 Unsupported License.
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in upregulation of Igf1 and Apoe, which both have been associated
with protective mechanisms in ALS45,46 and neurodegenerative
diseases such as Alzheimer’s disease47 and multiple sclerosis22.
Glut4 was also upregulated following treatment with the CPT1
antagonist, as previously described25.
A hallmark of disease in the SOD1 G93A model is the death of
lower-motor neurons in the spinal cord as well as disruption of
homeostasis in the muscles, including atrophy, denervation,
inflammation, and oxidative stress16,19,48. Based on this we
assessed the degree of muscle atrophy in the SOD1+ P and
SOD1+ E compared to Wt and found that both groups had
significant atrophy based on normalized weight of the tibialis
anterior muscles (Fig. 2n). In addition, we investigated differences
in the protein level of muscle RING-finger protein-1 (MuRF-1)
and atrogin-1 (Fig. 2o), which both represents markers of
atrophy. Wt mice had a significant lower level of atrogin-1 in
accordance with the muscle atrophy evaluation in Fig. 2n but no
difference was observed between the treatment groups. Next, we
evaluated the protein level of muscle skeletal receptor tyrosine-
protein kinase (MuSK), which protects against denervation49.
SOD1+ P mice had a significant decreased level compared to Wt
mice this was not the case for SOD1+ E mice (Fig. 2p). Further,
we evaluated the protein level of myogenin, which increases
during denervation50. The Wt mice had significantly lower levels
compared to SOD1+ P mice and the SOD1+ E mice had
significantly lower levels compared to SOD1+ P mice (Fig. 2q).
This could indicate that downregulation of CPT1 lipid metabo-
lism could play a role in diminishing denervation. However, this
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will require further investigations. One of the mechanisms
causing increased muscle pathology is inflammation. Therefore,
we also evaluated the levels of IL-10, IL-1β and TNF-α in the
tibialis anterior muscles. SOD1+ P mice had decreased levels of
IL-10 (Fig. 2r) and increased levels of IL-1β (Fig. 2s) and TNF-α
(Fig. 2t) compared to Wt and SOD1+ E mice. Finally, we
evaluated the gene expression profile of metabolic, inflammatory,
oxidative stress and denervation markers in the muscles (Fig. 2u).
SOD1+ P and SOD1+ E mice had significantly increased levels
of the active macrophage marker Cd68. In addition, both SOD1
groups had significantly downregulated Glut4 expression. SOD1
+ E mice had significantly increased expression of the oxidative
stress defense gene Nrf2, indicating that etomoxir potentially
diminished oxidative stress. Finally, we assessed the expression of
Chrna1, a marker of denervation, and found that both SOD1
groups had increased expression indicating denervation. In
summary, this indicate that etomoxir was able to alleviate the
disease progression and diminish disease processes such as
inflammation and oxidative stress to some extent but not in the
terminal stage. The SOD1 G93A mouse model is primarily
characterized by lower-motor neuron disease pathology, however,
this and other studies indicate that Mbp and Cd68 might also be
affected in the brain51 (Supplementary Fig. 3).
Downregulation of CPT1 lipid metabolism modulates CPT1A
and CPT1C labeling, myelination, astrogliosis, reactive
microglia, and motor neuron survival in the spinal cord in
SOD1 G93A mice. Following the clinical-relevant effects of
downregulating CPT1 lipid metabolism by etomoxir in the SOD1
G93A mouse model (Fig. 1) and the changes in metabolic,
inflammatory and oxidative stress markers in the lumbar spinal
cord (Fig. 2), we performed an immunohistochemical peroxidase
staining on the lumbar spinal cord to evaluate morphological
changes. To evaluate the effects of CPT1 downregulation, SOD1
G93A mice received etomoxir (SOD1+ E) or placebo (SOD1+
P) from day 70 and until termination at day 130. SOD1+ E mice
had significantly lower neuroscore and increased grip strength
compared to SOD1+ P mice (Fig. 1l, m). First, we evaluated
whether etomoxir affected the labeling of CPT1A. We found that
SOD1+ P mice had increased labeling compared to SOD1+ E
and Wt (Fig. 3a–c and Supplementary Fig. 4), which indicated
that etomoxir decreased the level of CPT1A, as previously
described23. Next, we evaluated whether etomoxir affected the
labeling of CPT1C. However, we did not find any indications of
difference in the labeling (Fig. 3d, e and Supplementary Fig. 4).
Previously, we and others have shown that CPT1 downregulation
results in diminished demyelination13,20. Further, demyelination
has been observed in the SOD1 G93A mouse model- and ALS
patients51,52. Therefore, we performed staining for MBP. In
agreement with the gene expression studies, SOD1+ P mice were
found to have decreased labeling of MBP, which was counteracted
by etomoxir (Fig. 3g–i and Supplementary Fig. 4).
Spinal cords from ALS patients and SOD1 mouse model are
characterized by astrogliosis and increased reactive astrocytes53.
Therefore, we assessed the labeling of the reactive astrocyte
marker, GFAP, in the spinal cord of SOD1 mice. SOD1+ P
mice had increased labeling of GFAP compared to Wt and
SOD1+ E mice (Fig. 4a–c and Supplementary Fig. 4), indicat-
ing increased reactive astrocytes in the SOD1+ P group.
Another hallmark of disease in ALS and the SOD1 G93A
model is neuroinflammation1. Therefore, we evaluated whether
etomoxir altered the labeling of IBA1, a marker of reactive
microglia and macrophages, in the lumbar spinal cord.
SOD1+ E mice had decreased labeling compared with
SOD1+ P mice (Fig. 4d–f), which was in accordance with the
inflammatory data presented in Fig. 2. Finally, we assessed
the labeling of ChAT, a marker of cholinergic neurons, in the
ventral horn in the lumbar spinal cord and found indications of
decreased labeling in SOD1+ P compared to SOD1+ E mice
(Fig. 4g–i). Overall, the immunohistochemical staining corre-
sponded to the data presented in Figs. 1 and 2.
Genetic downregulation of CPT1A activity delays disease onset
and alleviate clinical symptoms in SOD1 G93A mice. Based on
the effect of the CPT1 antagonist in the SOD1 G93A model and
our previous results showing that Cpt1aP479L/P479L mutated mice
are resistant to the experimental autoimmune encephalomyelitis
(EAE) model20, we tested the effect of crossing Cpt1aP479L/P479L
mutated female mice with SOD1 G93A male mice. The
Cpt1aP479L/P479L mouse strain was generated by mutating the
genomic Cpt1a gene, causing no expression changes in different
tissues20. The mutation results in a CPT1A activity of ~22%
compared to the wildtype protein in its’ homozygote form and
~70% activity in the heterozygote form54. SOD1 G93A mice with a
heterozygote Cpt1aWt/P479L (SOD1Wt/Cpt1a) and SOD1 G93A mice
with a homozygote Cpt1aP479L/P479L mutation (SOD1Cpt1a/Cpt1a)
Fig. 2 Downregulation of CPT1 activity by etomoxir potentially shifts metabolism towards glucose utilization and ameliorate disease mechanisms,
including inflammation, mitochondrial dysfunction, and oxidative stress. a Serum glucose levels. Mean mmol/L ± SEM. b Serum LDL levels. Mean mmol/
L ± SEM. c Serum HDL levels. Mean mmol/L ± SEM. d Serum LDL/HDL ratio levels. Mean mmol/L ratio ± SEM. e Serum NF-L levels. Mean pg/mL ± SEM,
f ChAT levels in lumbar spinal cord tissue homogenate. Median ng/mg total protein ± IQR. g CX3CR1 levels in lumbar spinal cord tissue homogenate. Mean
ng/mg total protein ± SEM. h IL-10 levels in lumbar spinal cord tissue homogenate. Mean pg/mg total protein ± SEM. i IL-1β levels in lumbar spinal cord
tissue homogenate. Mean pg/mg total protein ± SEM. j TNF-α levels in lumbar spinal cord tissue homogenate. Mean pg/mg total protein ± SEM. k–m Fold-
change gene expression of metabolic, glial, inflammatory and oxidative stress genes in lumbar spinal cord tissue. Mean normalized fold-change gene
expression ± SEM. n Weight of tibialis anterior muscle at termination. Weight of tissue were normalized to body weight and expressed as mean ± SEM.
o MuRF1 and atrogin-1 levels in tibialis anterior tissue homogenate. Mean ng/mg total protein ± SEM. p MuSK levels in tibialis anterior tissue homogenate.
Mean ng/mg total protein ± SEM. q Myogenin levels in tibialis anterior tissue homogenate. Mean ng/mg total protein ± SEM. r IL-10 levels in tibialis
anterior tissue homogenate. Mean pg/mg total protein ± SEM. s IL-1β levels in tibialis anterior tissue homogenate. Mean pg/mg total protein ± SEM. t TNF-
α levels in tibialis anterior tissue homogenate. Mean pg/mg total protein ± SEM. u Fold-change gene expression of metabolic, inflammatory, oxidative
stress and denervation genes in tibialis anterior tissue homogenate. Mean normalized fold-change gene expression ± SEM. Serum samples and tissue were
obtained at termination. All data was analyzed using one-way ANOVA followed by Tukey post hoc test or Kruskal–Wallis test followed by Dunns post hoc
test. N= 5–8 for serum analysis and 3–5 for all other experiments. Data are representative of one experiment. Gene expression was normalized to β-actin
and Gapdh. *Significant differences between groups in all analyses except gene expression experiments. *p≤ 0.05; **p≤ 0.01. Significant annotations in
gene expression experiments (one sign= p≤ 0.05, two signs= p≤ 0.01). *= SOD1+ P vs. SOD1+ E, %=Wt+P vs. SOD1+ P, #=Wt+P vs. SOD1+ E.
Wt=wildtype, SOD1= SOD1 G93A genotype, E= etomoxir, P= placebo, SEM= standard error of mean, IQR= interquartile range, LDL= low-density
lipoproteins, HDL=High-density lipoproteins, NF-L=Neurofilament light-chain, ChAT=Choline o-acetyltransferase, MuSK=Muscle skeletal receptor
tyrosine-protein kinase, MuRF1=Muscle RING-finger protein-1.
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were bred. The female SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a clinical
disease phenotypes were compared to female SOD1 G93A mice
without Cpt1a mutation (SOD1) (Fig. 5a).
The groups were tested weekly from day 70 by neurological
score, grip strength- and hangwire tests as previously described24.
The SOD1Wt/Cpt1a (median onset= 97 days) and SOD1Cpt1a/Cpt1a
(median onset= 103 days) had significantly (p= 0.0014) later
onset of tremor compared to SOD1 (median onset= 93 days)
(Fig. 5b). The SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a had signifi-
cantly lower neurological score, higher latency to fall on the
hangwire test and normalized grip strength at several time points
compared to SOD1 (Fig. 5c–e). No significant differences were
observed on weight (Fig. 5f). Furthermore, we evaluated the
spontaneous activity in the cylinder test and found that both
SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a had significantly higher
activity at day 70- and day 100 compared to SOD1 mice (Fig. 2g).
Based on the effects of downregulating CPT1 by the irreversible
CPT1 antagonist on visuospatial memory, we speculated whether
the decreased CPT1A activity affected memory in the mice with
Cpt1a mutations. Interestingly, SOD1Cpt1a/Cpt1a mice had a
significant higher visuospatial memory at day 70-, 100-, and
day 130 compared to SOD1 mice (Fig. 5i). The SOD1Wt/Cpt1a
mice had significant higher visuospatial memory compared
to SOD1 mice at day 100 and day 130 (Fig. 5i). Next, we
evaluated whether the downregulated CPT1A activity affected
survival. Remarkably, SOD1Wt/Cpt1a (median survival= 152) and
SOD1Cpt1a/Cpt1a (median survival= 153) had significantly (p=
0.032) increased survival compared to SOD1 mice (median
survival= 147) (Fig. 5j). We repeated the SOD1 x Cpt1a P479L
mutant experiment and evaluated neurological score until day
132 and found similar results (Fig. 5k). Finally, we evaluated the
survival in male SOD1Cpt1a/Cpt1a (median survival= 160 days)
and SOD1 mice (median survival= 149 days) and found
significant differences (p= 0.0016) according to the results from
the females (Fig. 5l). In general, the behavioral data was
consistent with the CPT1 antagonist study (Fig. 1). However,
minor effects were observed on the hangwire- and grip
strength tests. This is consistent with the fact that Cpt1a P479L
hetero- or homozygote mutations do not affect the activity of
CPT1B. In general, the Cpt1a P479L mutation delayed disease
progression and thereby confirmed the results from the CPT1
antagonist study.
Cpt1a P479L mutation restore glucose metabolism and
attenuates disease processes in the spinal cord and tibialis
anterior muscles in SOD1 G93A mice. In conjunction with the
CPT1 antagonist experiment, we assessed the effect of the
Cpt1aWt/P479L and Cpt1aP479L/P479L mutation on the serum levels
of glucose (Fig. 6a), LDL (Fig. 6b), HDL (Fig. 6c), and LDL/HDL
ratio (Fig. 6d) in SOD1 mice. Interestingly, we found that
downregulation of CPT1A activity in SOD1 mice increased
Fig. 3 Immunohistochemical staining in the lumbar spinal from the SOD1 G93A etomoxir experiment. a–c CPT1A staining in lumbar spinal cord fromWt,
SOD1+ P and SOD1+ E mice at day 130 indicating increased labeling in SOD1+ P mice (arrows) and pathological morphology of neurons (asterisks). d–f
CPT1C staining in lumbar spinal cord from Wt, SOD1+ P and SOD1+ E mice at day 130 indicating no difference in the labeling in SOD1+ P mice but
differences in the morphology of neurons (asterisks). g–i MBP staining in lumbar spinal cord from Wt, SOD1+ P and SOD1+ E mice at day 130 indicating
decreased labeling in SOD1+ P mice (arrows). All images are presented with 16x magnification. N= 2–4 animals per group. WT=wild-type, SOD1= SOD1
G93A genotype, E= etomoxir, P= placebo.
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glucose metabolism and restored lipoprotein levels towards a
reduced risk of ALS.
Based on the clinical-relevant effects by downregulation of
CPT1A activity by genetic mutation (Fig. 5) and the effects
of etomoxir (Figs. 1, 2), we speculated whether the serum level
of NF-L was affected by the mutation. SOD1Cpt1a/Cpt1a mice
had decreased levels of NF-L in serum compared to SOD1 mice
but no significant difference was detected (Fig. 6e). In addition,
we evaluated the protein level of ChAT in the spinal cord to
assess motor neuron death4. SOD1Cpt1a/Cpt1a mice had
significantly higher levels of ChAT compared to SOD1 mice
(Fig. 6f). This indicates that the death of motor neurons was
attenuated by the downregulated CPT1A activity due to the
P479L mutation.
In addition, we evaluated whether the downregulated CPT1A
activity affected inflammation as etomoxir did (Fig. 2). Therefore,
we evaluated the level of CX3CR1 in the spinal cord, as a marker
of reactive microglia and activated macrophages. Both SOD1Wt/
Cpt1a and SOD1Cpt1a/Cpt1a had decreased levels compared to
SOD1 mice (Fig. 6g), but it did not reach significance. Next, we
evaluated the levels of the anti-inflammatory cytokine IL-10
(Fig. 6h) and pro-inflammatory cytokines IL-1β (Fig. 6i) and
TNF-α (Fig. 6j) in the spinal cord. SOD1Cpt1a/Cpt1a had
significantly increased levels of IL-10 and both SOD1Cpt1a/Cpt1a
and SOD1Wt/Cpt1a had decreased levels of TNF-α compared to
SOD1 but no difference was found in IL-1β levels. This indicates
that the downregulated CPT1A activity modulates the inflam-
matory profile in the CNS.
Subsequently, we evaluated the gene expression profile of
metabolic, glial, inflammatory and oxidative stress markers in the
spinal cord. Overall, SOD1 mice had lower expression of, Cpt1c,
Pcg1α, Glut4, Apoe, Chat, Mbp, Nrf2 and Ho1 increased
expression of Casp1 (Fig. 6k–m), indicating pathological
processes such as mitochondrial dysfunction, downregulated
glucose metabolism, death of motor neurons, disruption of
myelin, oxidative stress and inflammation as in the etomoxir
study. Interestingly, the downregulated CPT1A activity resulted
in gene expressions associated with amelioration of disease such
as increased mitochondrial biogenesis, glucose metabolism,
survival of ChAT expressing neurons, myelination, oxidative
stress defense and diminished inflammation in the SOD1Wt/Cpt1a
and SOD1Cpt1a/Cpt1a mice (Fig. 6k–m). This indicates that the
genetic downregulation of CPT1A activity had similar effects as
the pharmacological downregulation of CPT1A and CPT1B
activity by etomoxir.
As previously described another hallmark of disease in the
SOD1 G93A model is the disruption of homeostasis in the
muscles including atrophy, denervation, inflammation, and
oxidative stress16,19,48. Based on the effects seen by etomoxir
treatment (Fig. 2n–t), we evaluated the effects of downregulating
CPT1A activity on muscle pathogenic processes in the tibialis
anterior muscles. SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a mice had a
Fig. 4 Immunohistochemical staining in the lumbar spinal from the SOD1 G93A etomoxir experiment. a–c GFAP staining in lumbar spinal cord from Wt,
SOD1+ P and SOD1+ E mice at day 130 indicating increased number of reactive astrocytes in the ventral horn in SOD1+ P mice (arrows) compared to Wt
and SOD1+ E mice. d–f IBA1 staining in lumbar spinal cord from Wt, SOD1+ P and SOD1+ E mice at day 130, indicating increased labeling and infiltration
of reactive microglia in the ventral horn in SOD1+ P mice (arrows) compared to SOD1+ E and Wt mice. g–i ChAT staining in lumbar spinal cord from Wt,
SOD1+ P and SOD1+ E mice at day 130 indicating decreased labeling in SOD1+ P mice (arrows) and pathological morphology of neurons. All images are
presented with x16 magnification. N= 2–4 animals per group. WT=wild-type, SOD1= SOD1 G93A genotype, E= etomoxir, P= placebo.
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lower degree of muscle atrophy compared to SOD1 mice (Fig. 6n),
but the difference was not significant. In addition, SOD1Wt/Cpt1a
and SOD1Cpt1a/Cpt1a mice had lower levels of MuRF1 (Fig. 6o) in
accordance with the higher normalized weight of muscle tissue
(Fig. 6n). Further, SOD1Wt/Cpt1a mice had a tendency towards a
significantly lower level of the atrophy marker atrogin-116
compared to SOD1 mice (Fig. 6o). Next, we evaluated the
protein level of MuSK and found that SOD1Cpt1a/Cpt1a mice had
higher levels compared to SOD1 mice (Fig. 6p). In addition,
SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a mice had significantly lower
protein levels of myogenin, which could indicate a lower degree of
denervation in these mice (Fig. 6q). However, this will require
further experiments to confirm. As in the spinal cord, inflamma-
tion plays a central role in the progression of disease in the
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muscles. Therefore, we also evaluated the levels of IL-10, IL-1β
and TNF-α in the tibialis anterior muscles. SOD1Cpt1a/Cpt1a mice
had increased levels of IL-10 (Fig. 6r) and both SOD1Wt/Cpt1a and
SOD1Cpt1a/Cpt1a mice had decreased levels of TNF-α (Fig. 6t). No
difference was found in the levels of IL-1β between the groups
(Fig. 6s). This indicates that the downregulation of CPT1A
activity attenuated inflammation in the tibialis anterior muscles.
Finally, we evaluated the gene expression profile of inflamma-
tory, oxidative stress and denervation markers in the muscles
(Fig. 6u). SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a mice had decreased
expression of Cd68 compared to SOD1 mice (Fig. 6u) in
accordance with the decreased level of inflammatory cytokines
in the muscles (Fig. 6r–t). SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a
mice had decreased expression of the oxidative defense gene Nrf2
compared to SOD1 mice (Fig. 6u), which could indicate that
oxidative stress levels were lower or that Nrf2 upregulation was
impaired. Finally, we assessed the expression of Chrna1 and
found that both SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a had
decreased expression compared to SOD1 mice (Fig. 6u), which
indicates that the downregulated CPT1A activity possibly
ameliorated denervation. In summary, these findings indicate
that downregulation of CPT1A activity was able to alleviate the
disease progression and diminish disease processes such as
inflammation, oxidative stress, decrease the death of ChAT
expressing neurons and ameliorate denervation to some extent.
Upregulation of CPT1 activity by 60% saturated high-fat diet
accelerates disease progression in the SOD1 G93A mouse
model. Downregulation of CPT1 isoforms A and B activity by
etomoxir (Figs. 1, 2) and CPT1A activity by the Cpt1a P479L
mutation (Figs. 5, 6) delayed disease progression and attenuated
multiple pathological mechanisms including inflammation and
oxidative stress in the SOD1 G93A mouse model. Based on this
we hypothesized that the upregulation of CPT1A and CPT1B
activity would exacerbate disease progression and severity. High-
fat diets (HFD) with a high level of saturated fatty acids increases
the level of acyl-CoA55, CPT1A56 and CPT1B activity57 and
thereby β-oxidation in the periphery, including liver and muscle
tissue. In addition, HFD increases pyruvate dehydrogenase
kinase-4 (PDK4) activity and thereby downregulates the pyruvate
dehydrogenase complex and thus the conversion of pyruvate into
acetyl-CoA to be used in the Krebs cycle58. HFD also down-
regulates the glucose transporters within the CNS and increases
insulin resistance in the periphery and CNS, which potential
results in decreased glucose metabolism59. Previous studies on the
effects of HFD in in vivo models of ALS and ALS patients have
resulted in inconsistent conclusions60–65 due to large differences
in the composition of the diets61. Therefore, we tested whether a
western HFD, 60% saturated fats, affected the disease progression
in the SOD1 G93A model.
SOD1 G93A mice were fed with a HFD (SOD1+HFD)
(Fig. 7a) and compared with SOD1 G93A mice fed a normal diet
(ND) (SOD1+ND). SOD1+HFD had a significant (p= 0.0052)
earlier onset of tremor (median onset= 91 days) compared to
SOD1+ND (median onset = 98 days), loss of normalized grip
strength and lower latency to fall on the hangwire test (Fig. 7b–e).
Interestingly, wildtype mice receiving HFD (Wt+HFD) also had
a significant decrease in normalized grip strength compared to
wildtype mice receiving ND (Wt+ND) (Fig. 7d). HFD resulted
in a significant weight gain for both Wt+HFD and SOD1+
HFD compared to their respective controls (Fig. 7f). HFD
resulted in a significantly lower activity in the cylinder test
(Fig. 7g). SOD1 mice had a significantly lower number of entries
in the y-maze, which is in accordance with motor neuron
degeneration (Fig. 7h). Both Wt+HFD and SOD1+HFD had a
significant decrease in their visuospatial memory based on the y-
maze test in agreement with previous studies in Wt mice
receiving HFD (Fig. 7i). Finally, we evaluated whether HFD
affected survival. We found that SOD1+HFD (median survival
= 140) had significantly (p= 0.0083) decreased survival com-
pared to SOD1+ND (median survival= 147). Overall, our data
indicated that HFD results in a more severe disease phenotype in
the SOD1 G93A model. Differences seen from other studies using
HFD could possibly be attributed to genetic background and
differences in the composition of the HFD9,66,67.
60% HFD results in hyperglycemia, decreased glucose meta-
bolism, and exacerbates disease processes in the spinal cord
and tibialis anterior muscles in SOD1 G93A mice. Based on the
exacerbation of clinical-relevant phenotype in SOD1 mice fed a
60 % HFD, we assessed the serum levels of glucose, LDL, HDL,
and LDL/HDL ratio. SOD1+HFD had significantly increased
glucose levels compared to SOD1+ND and Wt+ND (Fig. 8a),
indicating hyperglycemia, possibly due to decreased glucose
metabolism. In addition, SOD1+HFD had significant differences
in the level of LDL (Fig. 8b), HDL (Fig. 8c), and LDL/HDL ratio
(Fig. 8d), which were in accordance with the differences seen for
the SOD1+ P group (Fig. 2b–d). This indicated that 60 % HFD
resulted in downregulated glucose utilization and increased
lipoprotein levels in the serum, pointing towards metabolic
alternations.
Next, we evaluated the protein level of ChAT in the spinal cord
to assess whether HFD affected motor neuron death4. ChAT was
significantly decreased in both SOD1+ND and SOD1+HFD
Fig. 5 Genetic inhibition of CPT1A ameliorates clinical symptoms and delays disease progression in the SOD1 G93A mouse model. a Experimental
setup, mice were evaluated with behavioral tests from day 70 (baseline) and tested weekly until day 150. b Time point for onset of disease defined as
visible tremor in hindlimbs, log-rank survival analysis. c Neuroscore was assessed once a week. Mean neuroscore ± SEM. d Hangwire test was performed
once a week. Mean latency to fall of the grid ± SEM. e Grip strength was measured once a week from day 70. Data are presented as mean normalized
strength ± SEM. f Mean body weight expressed in grams ± SEM. g Cylinder test was performed at day 70, 100, and 130. Mean rears ± SEM. One-way
ANOVA with Tukey post hoc test. h Y-maze test was conducted at day 70, 100, and 130. Mean number of entries ± SEM. One-way ANOVA with Tukey
post hoc test i Y-maze test was conducted at day 70, 100, and 130. Mean spontaneous alternation percentage ± SEM. One-way ANOVA with Tukey post
hoc test. j Survival analysis for females, survival was defined as neuroscore below 4, log-rank test. k Mean neuroscore for SOD1 mice evaluated from day
70 and until day 132 ± SEM. l Survival analysis for females, survival was defined as neuroscore below 4, log-rank test. Animals were tested weekly from day
70 of age until day 148. N= 5–10, except for tremor onset (n= 12–16) and survival analyses (n= 8–10 for females, n= 10–25). Data are representative of
two independent animal experiments for females from day 70 and until day 150 and one for day 70 and until day 132. If nothing else is noted, data was
analyzed using repeated measure two-way ANOVA followed by Tukey post hoc test. *Significant differences between SOD1Cpt1a/Cpt1a and SOD1,
#significant differences between SOD1Wt/Cpt1a and SOD1 in behavioral tests. *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001, ****p≤ 0.0001. SOD1= SOD1 G93A
genotype, SOD1Wt/Cpt1a= SOD1 G93A mice with heterozygote Cpt1a P479L mutation, SOD1Cpt1a/Cpt1a= SOD1 G93A mice with homozygote Cpt1a P479L
mutation. Mouse figure used in experimental setup figures were obtained from; https://smart.servier.com/ and used according to the Creative Commons
Attribution 3.0 Unsupported License.
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compared to Wt+ND (Fig. 8e). However, the SOD1+HFD mice
had the lowest level of ChAT in the spinal cord, possibly
indicating higher disease activity.
In addition, we evaluated whether the upregulated CPT1
activity due to 60 % HFD affected inflammation in the spinal
cord. In general, SOD1 mice had decreased levels of IL-10
(Fig. 8f) and increased levels of IL-1β (Fig. 8g) and TNF-α
(Fig. 8h). SOD1+HFD mice had significantly increased levels of
IL-1β compared to SOD1+ND mice (Fig. 8g) indicating possibly
increased inflammation. Following these findings, we assessed
changes in the gene expression profile of metabolic, glial,
inflammatory and oxidative stress markers in the spinal cord.
study. Interestingly, HFD resulted in changes in expression of
Cpt1a, Cpt1c, Pcg1α, Iba1, Chat, Gfap, Cd68, Ho1, Nox2 and Nrf2
(Fig. 8i, j). This indicates that in general, HFD results in changes
associated with increased disease activity such as decreased
mitochondrial biogenesis, death of motor neurons, inflammation
and decreased defense against oxidative stress in the spinal cord.
We previously found that downregulation of CPT1 activity
attenuated pathological mechanisms in the tibialis anterior
muscle (Figs. 2 and 6). Therefore, we evaluated whether the
upregulation of CPT1B due to 60% HFD had any detrimental
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effects in the tibialis anterior muscle. 60% HFD resulted in
increased muscle atrophy (Fig. 8l) and decreased levels of MuSK
(Fig. 8m), indicating increased denervation. Unexpectedly, we did
not observe an increase in the level of MuRF1 in SOD1+HFD
mice (Fig. 8n). Additionally, we evaluated whether the diet
affected the level of anti- and pro-inflammatory cytokines in the
tibialis anterior muscle. SOD1+HFD mice had a tendency to
lower level of IL-10, which were however not statistical significant
(Fig. 8o) no changes were observed in IL-1β (Fig. 8p) and TNF-α
level (Fig. 8q). Finally, we investigated whether 60% HFD resulted
in changes in gene expression in the muscles. HFD resulted in
increased β-oxidation in the muscle, inflammation, and decreased
glucose metabolism (Fig. 8r), which is consistent with previous
studies. In general, the gene expression profiles in the muscle
tissue were accordant with those in the spinal cord. Interestingly,
Cpt1c gene expression was found to be decreased in the brain
following HFD in both Wt and SOD1 G93A mice (Supplemen-
tary Fig. 3). Knockout of Cpt1c decreases cognitive function42,43,
which could indicate that the decreased Cpt1c expression in the
HFD groups play a role in the decreased performance in the Y-
maze test (Fig. 7i).
In summary, these findings indicate that upregulation of
CPT1A and CPT1B activity resulted in a more aggressive clinical-
relevant behavior and aggravated disease processes such as
inflammation, oxidative stress, increased the death of ChAT
expressing neurons and possibly muscle atrophy and denervation.
Upregulation of CPT1 activity by corticosterone accelerates
disease progression in the SOD1 G93A mouse model. Any
imbalances to an organism’s homeostasis elicit a complex stress
response that causes activation of the neuroendocrine and auto-
nomic system. One of the essential systems in the stress response
is the hypothalamic-pituitary-adrenal (HPA) axis68. During acute
stress, such as critical sickness, the stress response is beneficial for
survival. However, prolonged stress, due to psychological or
physiological circumstances, causes an overactivation of the
HPA-axis resulting in chronic high levels of glucocorticoids
(cortisol). High levels of cortisol, in turn, result in increased
activity of PDK4, which downregulates glucose metabolism69. In
addition, cortisol promotes insulin resistance, which forces
metabolism towards lipolysis70,71 and increases β-oxidation72.
These findings could indicate that increased levels of
glucocorticoids could increase the activity of CPT1. Several stu-
dies support the importance of a dysregulation of the HPA-axis in
ALS and the SOD1 G93A mouse model. ALS patients have been
found to have increased morning cortisol blood levels and a
disruption of the cortisol awakening response73,74. Studies have
shown that prolonged high levels of cortisol leads to glucocorti-
coid receptor resistance, which eventually results in failure to
downregulate the inflammatory response75. Chronic restraint
stress in SOD1 G93A mice increased the level of corticosterone,
which correlated with decreased survival and increased
inflammation76.
Based on this, we hypothesized that increased levels of
glucocorticoids would result in a downregulation of glucose
metabolism and an upregulation of CPT1-mediated lipid
metabolism. Therefore, we tested the effect of administering the
mouse equivalent of cortisol, corticosterone, to SOD1 G93A mice
from day 70 and until day 100 (Fig. 9a). SOD1 G93A mice
receiving corticosterone (SOD1+ CORT) had significant (p=
0.03) earlier onset of tremor (median onset= 79 days) compared
to SOD1+V (median onset= 87 days), higher neurological
score, decreased latency to fall and decreased normalized grip
strength (Fig. 9b–e). Interestingly, also wildtype mice receiving
corticosterone (Wt+CORT) had a significant decrease in
normalized grip strength (Fig. 9e). SOD1 G93A+CORT and
Wt+CORT had a significant increase in weight (Fig. 9f), which
could indicate changes in metabolism, according to the previously
presented literature. Further, SOD1+CORT had a significant
reduction in activity in the cylinder test (Fig. 9g) and visuospatial
memory in the y-maze test (Fig. 9h).
We terminated a group of mice at day 100 to evaluate whether
the oral administration of CORT affected serum CORT levels.
Serum levels of CORT was significantly increased in the SOD1
+ CORT mice at day 100 compared to SOD1+V (Fig. 9i), in
accordance with previous studies using chronic restraint
stress in SOD1 mice76. Next, we examined whether CORT
affected glucose levels in serum as an indication of down-
regulated glucose metabolism. SOD1+ CORT mice had higher
serum glucose levels (Fig. 9j), indicating downregulated utiliza-
tion of glucose.
Finally, we evaluated changes in gene expression of metabolic,
inflammatory and oxidative stress genes in spinal cord and tibialis
anterior tissue obtained at day 130. SOD1+CORT mice had
Fig. 6 Downregulation of CPT1A activity by Cpt1a P479L mutations potentially shifts metabolism towards glucose utilization and ameliorate disease
mechanisms including inflammation, mitochondrial dysfunction, and oxidative stress. a Serum glucose levels. Mean mmol/L ± SEM. b Serum LDL levels.
Mean mmol/L ± SEM. c Serum HDL levels. Mean mmol/L ± SEM. d Serum LDL/HDL ratio levels. Mean mmol/L ratio ± SEM. e Serum NF-L levels. Mean
pg/mL ± SEM, f ChAT levels in lumbar spinal cord tissue homogenate. Mean ng/mg total protein ± SEM. g CX3CR1 levels in lumbar spinal cord tissue
homogenate. Mean ng/mg total protein ± SEM. h IL-10 levels in lumbar spinal cord tissue homogenate. Median pg/mg total protein ± IQR. i IL-1β levels in
lumbar spinal cord tissue homogenate. Mean pg/mg total protein ± SEM. j TNF-α levels in lumbar spinal cord tissue homogenate. Mean pg/mg total
protein ± SEM. k–m Fold-change gene expression of metabolic, glial, inflammatory and oxidative stress genes in lumbar spinal cord tissue. Mean
normalized fold-change gene expression ± SEM. n Weight of tibialis anterior muscle at termination. Weight of tissue were normalized to body weight and
expressed as mean ± SEM. o MuRF1 and atrogin-1 levels in tibialis anterior tissue homogenate. Mean ng/mg total protein ± SEM. p MuSK levels in tibialis
anterior tissue homogenate. Mean ng/mg total protein ± SEM. qMyogenin levels in tibialis anterior tissue homogenate. Mean ng/mg total protein ± SEM. r
IL-10 levels in tibialis anterior tissue homogenate. Mean pg/mg total protein ± SEM. s IL-1β levels in tibialis anterior tissue homogenate. Mean pg/mg total
protein ± SEM. t TNF-α levels in tibialis anterior tissue homogenate. Mean pg/mg total protein ± SEM. u Fold-change gene expression of metabolic,
inflammatory, oxidative stress and denervation genes in tibialis anterior tissue homogenate. Mean normalized fold-change gene expression ± SEM. Serum
samples and tissue were obtained at termination. All data was analyzed using one-way ANOVA followed by Tukey post hoc test or Kruskal–Wallis test
followed by Dunns post hoc test. N= 3–8 for serum analysis and 3–5 for all other experiments. Data are representative of one experiment. Gene expression
was normalized to β-actin and Gapdh. *Significant differences between groups in all analyses except gene expression experiments. *p≤ 0.05; **p≤ 0.01.
Significant annotations in gene expression experiments (one sign= p≤ 0.05, two signs= p≤ 0.01). *= SOD1 vs. SOD1Cpt1a/Cpt1a, %= SOD1Wt/Cpt1a vs.
SOD1Cpt1a/Cpt1a, #= SOD1 vs. SOD1Wt/Cpt1a. SOD1= SOD1 G93A genotype, SOD1Wt/Cpt1a= SOD1 G93A mice with heterozygote Cpt1a P479L mutation,
SOD1Cpt1a/Cpt1a= SOD1 G93A mice with homozygote Cpt1a P479L mutation, SEM= standard error of mean, IQR= interquartile range, LDL= low-density
lipoproteins, HDL=High-density lipoproteins, NF-L=Neurofilament light-chain, ChAT=Choline o-acetyltransferase, MuSK=Muscle skeletal receptor
tyrosine-protein kinase, MuRF1=Muscle RING-finger protein-1.
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increased expression of Cpt1a (Fig. 9k) and Cd68 (Fig. 9l) but no
change in Nox2 (Fig. 9m) in the spinal cord compared to SOD1
+V mice. We also found that SOD1+CORT mice had increased
expression of Cpt1b (Fig. 9n), Cd68 (Fig. 9o) and decreased
expression of Glut4 (Fig. 9p) in the tibialis anterior muscle. This
indicates that CORT resulted in a shift towards β-oxidation and
increased reactivity of microglia and macrophages.
In summary, CORT treatment resulted in a more aggressive
disease phenotype, which is consistent with previously studies in
the SOD1 G93A model76.
Regulation of CPT1 activity results in alternations in the gut
microbiome in the SOD1 G93A mouse model. In the recent
decades, studies have reported associations between changes in
the gut microbiota and neurodegenerative diseases including
ALS77,78. The gut microbiota modulates inflammation, HPA-axis
activity, metabolism and other disease processes associated with
ALS79–82. Alternations in the gut microbiome in SOD1 G93A
mice correlates with inflammation, motor neuron and muscle
pathology80. Further, the changes in metabolism due to the SOD1
G93A mutation could also result in changes in the gut
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microbiome due to the presence of metabolites in the body, which
benefit some and hamper other bacteria. In addition, etomoxir
and CPT1A lipid metabolism has previously been shown to
modulate bacteria and the gut microbiome24. Based on this, we
hypothesized that downregulation of CPT1 and CPT1A activity
would change the gut microbiome towards a disease ameliorating
composition and a disease aggravating composition by 60% HFD
or CORT.
First, we examined whether SOD1 G93A mice have changes in
their gut microbiota at day 70 compared to wildtype mice to
assess whether disruption of the gut microbiota could play a role
in disease establishment and progression. SOD1 mice presented
with indications of increased intra-group microbiota diversity (α-
diversity) based on Shannon, Simpson, inversed Simpson, Chao1,
ACE and Pielou measures (Supplementary Fig. 5a, b). In addition,
we evaluated inter-group microbiota diversity (β-diversity) based
on principal component analysis (PCA). The PCA indicated that
SOD1 and Wt mice had different microbial fecal compositions
(Supplementary Fig. 6a). Following the evaluation of α- and β-
diversity, we assessed the most relative abundant bacterial
communities at phyla (Supplementary Fig. 7a), family (Supple-
mentary Fig. 8a) and genus level using heatmap (Fig. 10a).
Further, we performed differential abundance testing using
DESeq2 with Benjamin–Hochberg adjustment. The differential
abundance testing found multiple significant differences based on
observed operational taxonomic units (OTU) (Supplementary
Data 1a). This indicated that SOD1 G93A mice have changes in
their microbiome before visible disease onset in accordance with
the literature80.
Based on this, we compared the fecal gut microbiome from
SOD1 G93A mice at day 70 with fecal samples obtained from
SOD1 G93A mice at day 130 and healthy Wt mice. SOD1 mice at
day 130 had decreased α-diversity compared to SOD1 mice at day
70 (Supplementary Fig. 5c–d). In addition, PCA analysis
indicated inter-group differences in the composition of the fecal
gut microbiome between the groups (Supplementary Fig. 6b).
Further, we assessed the most relative abundant bacterial
communities at phyla (Supplementary Fig. 7b), family (Supple-
mentary Fig. 8b) and genus level using heatmap (Fig. 10b). This
indicates that the fecal gut microbiome change as the disease
progresses. Following the evaluation of the most abundant
communities, we performed differential abundance testing using
DESeq2 with the Benjamin–Hochberg adjustment to evaluate
differences between SOD1 G93A mice at day 70 compared to day
130. The differential abundance testing found multiple significant
differences between the fecal gut microbiome in the SOD1 G93A
mice at day 70 compared to day 130 (Supplementary Data 1b).
Overall, the SOD1 day 130 group had a significant increase in
communities associated with neurodegenerative diseases (Supple-
mentary Data 1b)80,83.
Following the findings that the gut microbiome plays a role in
the establishment- and progression of disease in SOD1 G93A
mice. We evaluated whether etomoxir affected the composition of
the fecal gut microbiome in SOD1 G93A mice at day 130
following 60 days of treatment. First, we evaluated the α-diversity
(Supplementary Fig. 5e, f) and found that both SOD1 groups had
decreased α-diversity based on Chao1 and ACE measures. We
also found indication of differences in β-diversity between the
SOD1+ E and SOD1+ P group at day 130 (Supplementary
Fig. 6c). Following the different clustering on the PCA plot, we
assessed the highest relative abundant bacterial communities at
phyla (Supplementary Fig. 7c), family (Supplementary Fig. 8c)
and genus level (Fig. 10c) using heatmaps. Following the
evaluation of the most abundant communities, we also performed
differential abundance testing using DESeq2 with the
Benjamin–Hochberg adjustment to evaluate differences between
SOD1+ E and SOD1+ P mice. The differential abundance
testing found multiple significant differences between the two
treatment groups (Supplementary Data 1c). In general, the
SOD1+ E group had a significant decrease in Rikenellaceae,
Akkermansiaceae, Gastranaerophilales-, and ϒ-proteobacteria
compared to the SOD1 G93A+ P group. An increase in these
communities has been associated with neurodegenerative dis-
eases, inflammation in the intestine84, increased lipid metabolism
and degradation of the mucin layer85. This indicated that
downregulation of CPT1A activity affected the composition of
the gut microbiome, which could explain some of the differences
in metabolic and inflammatory markers in the SOD1+ E mice
compared with SOD1+ P mice (Fig. 2).
After we established that CPT1 lipid metabolism modulated
the gut microbiome in SOD1 G93A mice, we investigated
whether SOD1Cpt1a/Cpt1a mice had changes in their microbiome
compared to SOD1 G93A mice at day 130, which could account
for some of the differences seen in metabolic and inflammatory
markers (Fig. 6). First, we assessed α-diversity and found that the
SOD1Cpt1a/Cpt1a group had significantly increased α-diversity
compared to SOD1 G93A mice (Supplementary Fig. 5g, h). Next,
β-diversity was evaluated using PCoA plot. SOD1Cpt1a/Cpt1a and
SOD1 G93A mice clustered into two separate groups indicating
differences inter-group gut microbiome diversity (Supplementary
Fig. 6d). Based on the PCoA plot we evaluated the most abundant
bacterial communities at phyla (Supplementary Fig. 7d), family
(Supplementary Fig. 8d) and genus level (Fig. 10d) using heatmap
and found indications of differences. Following the evaluation of
the most abundant communities, we performed differential
abundance testing using DESeq2 with the Benjamin–Hochberg
adjustment. The differential abundance testing found multiple
significant differences between the groups Overall, the most
remarkable changes were seen by the significant increase in
Lachnospiraceae and Odoribacter (Supplementary Data 1d).
Fig. 7 High-fat diet accelerates disease progression in the SOD1 G93A mouse model. a Experimental setup, mice were randomized into HFD or ND at
approximately day 70 (baseline) and tested weekly until 10 weeks since baseline (day 150). b Time point for onset of disease defined as visible tremor in
hindlimbs (n= 7), log-rank survival analysis. c Neuroscore was assessed once a week. Data are presented as means ± SEM (n= 7). d Hangwire test was
performed once a week. Data are presented as mean latency to fall of the grid ± SEM (n= 7). e Grip strength was measured once a week from day 70.Data
are presented as means ± SEM (n= 4–7). f Mean body weight expressed in grams ± SEM (n= 4–7). g Cylinder test was performed at day 70 and day 130.
Data are presented as mean ratio rears between day 130 and baseline ± SEM (n= 4–7). h Y-maze test was conducted at day 70 and day 100. Data are
presented as mean entries ± SEM (n= 4–7). i Y-maze test was conducted at day 70 and day 100. Data are presented as mean spontaneous alternation
percentage ± SEM (n= 4–7). j Survival was defined as neuroscore below 4, (n= 7), log-rank survival analysis. If nothing else is noted, data was analyzed
using repeated measure two-way ANOVA followed by Tukey post hoc test. Data are representative of two experiments. *Significant differences between
SOD1+ND and SOD1+HFD, $significant difference between SOD1 and Wt, #significant differences between Wt+ND and Wt+HFD in behavioral tests.
*Significant differences between groups in serum analyses. *p≤ 0.05; **p≤ 0.01; #p≤ 0.05; ##p≤ 0.01, $p≤ 0.05, $$p≤ 0.01. Wt=wildtype, SOD1=
SOD1 G93A genotype, ND= normal diet, HFD=High-fat diet. Mouse figure used in experimental setup figures were obtained from; https://smart.servier.
com/ and used according to the Creative Commons Attribution 3.0 Unsupported License.
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Interestingly, Odoribacter has been associated with resistance to
HFD induction, healthy fasting serum lipid profile (high HDL
and low LDL), polarization of macrophages towards the anti-
inflammatory M2 type and decreased levels of TNF-α86. This
indicated that the decreased CPT1A activity resulted in a shift in
the gut microbiota in the SOD1 G93A mouse model, which
potentially further could affect metabolism and inflammation.
Overall, the results from etomoxir and Cpt1a P479L mutation
experiments indicated that downregulation of CPT1 activity
resulted in a shift in the gut microbiome, which could affect the
attenuation of some disease mechanisms.
Following these findings, we hypothesized that the upregulation
of CPT1 activity by 60% HFD would affect the composition of the
fecal gut microbiome and thereby potentially affect disease
mechanisms such as inflammation. HFD resulted in a decreased
α-diversity (Supplementary Fig. 5i, j) and a shift in β-diversity
(Supplementary Fig. 6e). Next, we evaluated the most abundant
bacterial communities at phyla (Supplementary Fig. 7e), family
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(Supplementary Fig. 8e) and genus level (Fig. 10e) using heatmap
and found multiple differences between the groups including an
increase in Lactobacillus, Streptococcaceae, Desulfovibrionaceae and a
decrease in Lachnospiraceae. In addition, we performed differential
abundance testing using DESeq2 with the Benjamin–Hochberg
adjustment. The differential abundance testing found multiple
significant differences between the groups (Supplementary Data 1e).
Increased levels of species of Lactobacillus87 and Streptococcaceae88
are associated with increased intestinal inflammation and oxidative
stress, which could affect both the periphery and CNS and thereby
play a role in the exacerbated disease progression in the SOD1+
HFD mice (Figs. 7, 8).
Finally, we evaluated whether CORT affected the composition
of the fecal gut microbiome in SOD1 G93A mice and thereby
possibly disease mechanisms at day 130, 30 days after CORT
treatment was initiated. The α-diversity was increased in the
SOD1+ CORT mice compared to SOD1 mice (Supplementary
Fig. 5k, l). CORT administration resulted in changes in β-
diversity in the SOD1 and Wt mice (Supplementary Fig. 6f). Next,
we evaluated the most abundant bacterial communities at phyla
(Supplementary Fig. 7f), family (Supplementary Fig. 8f) and
genus level using heatmap and found multiple differences
between the groups including an increase in Lactobacillus in
both SOD1+CORT and Wt+CORT mice (Fig. 10f). The
differential abundance testing found multiple significant differ-
ences between the groups (Supplementary Data 1f). Increased
levels of species of Lactobacillus87 are associated with increased
inflammation and oxidative stress, which could play a role in the
exacerbated disease progression in the SOD1+CORT mice
(Fig. 7, 8).
In summary, we found that SOD1 G93A mice present with
pathological changes in the gut microbiome, which develops as
the disease progresses. The downregulation of CPT1 activity
results in modulation of the gut microbiome, which could be
relevant in delaying the disease progression together with target
engagement in the periphery and CNS. Finally, we found that
HFD and CORT results in a further disruption of the gut
microbiome that could result in exacerbation of disease process
such as inflammation.
Discussion
CNS diseases represents an increasing health concern based on
the aging world population. Even though several genetic risk
factors have been identified for ALS, environmental and gene-
environment interaction probably account for most of the ALS
cases. In this study, we provide evidence that dysregulated
metabolism, and specifically CPT1 regulated lipid metabolism
plays a central role in the SOD1 G93A mouse model of ALS. We
show that pharmaceutical downregulation of CPT1 results in a
slower disease progression when applied in the early phase of the
disease, and that it has effects on several aspects of the disease
phenotype, including motor and non-motor behavior. Further-
more, we provide data indicating effects if the treatment is
initiated at a more progressed disease phase. In addition, the
SOD1 G93AWt/Cpt1a and SOD1 G93ACpt1a/Cpt1a behavior data
indicate that the slower disease progression is because of the
diminished CPT1A activity, underpinning the potential of tar-
geting dysregulated CPT1 lipid metabolism. These data underpin
the effect seen in the Inuit population, which have the same
CPT1A mutation as present in the mouse strain and show a
reduced incidence of ALS21. In accordance with this, we have
previously shown that Cpt1a P479L mice are resistant to
EAE induction20, and that etomoxir results in diminished
inflammation23 and autoantibody-antigen activity in EAE rats22.
Previously, it was accepted that the CNS only utilized glucose as a
substrate for energy production, but within recent years, it has
become evident that the CNS can metabolize lipids to produce
energy89,90. However, increased β-oxidation can result in
increased production of reactive oxygen species and mitochon-
drial dysfunction and thereby disruption of homeostasis in the
CNS14. Here, we report that downregulation of CPT1A and
CPT1B by etomoxir- and CPT1A by Cpt1a P479L mutation
impact several disease mechanisms, including inflammation,
myelination, glucose metabolism and oxidative stress. Accord-
ingly, downregulation of CPT1 by etomoxir results in ameliora-
tion of autoreactive T-cells13, antigen presentation by dendritic
cells91 and diminished autoreactive antibodies22, which is in
accordance with our findings indicating lower levels of pro-
inflammatory cytokines. In addition, we found upregulation of
Apoe gene expression following etomoxir treatment and Cpt1a
P479L mutation. Decreased Apoe is associated with increased
inflammation and disrupted blood brain barrier (BBB)22 pointing
towards that targeting CPT1 results in modulation of multiple
disease mechanisms. Etomoxir treated SOD1 mice had dimin-
ished labeling of CPT1A in the spinal cord, illustrating that
etomoxir downregulates CPT1A, consistent with previous
Fig. 8 60% HFD results in exacerbation of disease mechanisms in the SOD1 G93A mouse model. a Serum glucose levels in serum samples obtained at
termination. Mean mmol/L ± SEM. b Serum LDL levels in serum samples obtained at termination. Mean mmol/L ± SEM. c Serum HDL levels in serum
samples obtained at termination. Mean mmol/L ± SEM. d Serum HDL levels in serum samples obtained at termination. Mean mmol/L ± SEM. e ChAT
levels in lumbar spinal cord tissue homogenate obtained at termination. Mean ng/mg total protein ± SEM. f IL-10 levels in lumbar spinal cord tissue
homogenate obtained at termination. Mean pg/mg total protein ± SEM. g IL-1β levels in lumbar spinal cord tissue homogenate obtained at termination.
Mean pg/mg total protein ± SEM. h TNF-α levels in lumbar spinal cord tissue homogenate obtained at termination. Mean pg/mg total protein ± SEM. i–k
Fold-change gene expression of metabolic, glial, inflammatory and oxidative stress genes in lumbar spinal cord tissue obtained at termination. Mean
normalized fold-change gene expression ± SEM. l Weight of tibialis anterior muscle obtained at termination. Weight of tissue was normalized to body
weight and expressed as mean ± SEM. m MuSK levels in tibialis anterior tissue homogenate obtained at termination. Mean ng/mg total protein ± SEM.
n MuRF1 levels in tibialis anterior tissue homogenate obtained at termination. Mean ng/mg total protein ± SEM. o IL-10 levels in tibialis anterior tissue
homogenate obtained at termination. Mean pg/mg total protein ± SEM. p IL-1β levels in tibialis anterior tissue homogenate obtained at termination. Mean
pg/mg total protein ± SEM. q TNF-α levels in tibialis anterior tissue homogenate obtained at termination. Mean pg/mg total protein ± SEM. r Fold-change
gene expression of metabolic, inflammatory and denervation genes in tibialis anterior tissue obtained at termination. Mean normalized fold-change gene
expression ± SEM. All data was analyzed using two-way ANOVA followed by Tukey post hoc test. N= 4–7 for serum analysis and 3–5 for all other
experiments. Data are representative of one experiment. Gene expression was normalized to β-actin and Gapdh. *Significant differences between groups in
all analyses except gene expression experiments. *p≤ 0.05; **p≤ 0.01. Significant annotations in gene expression experiments (one= p≤ 0.05, two= p≤
0.01), #=Wt+HFD vs. SOD1+HFD, %=Wt+ND vs. SOD1+HFD, o=Wt+ND vs. SOD1+ND, ¤=Wt+HFD vs. SOD1+ND, $=Wt+ND vs. Wt
+HFD, *= SOD1+ND vs. SOD1+HFD Wt=wildtype, SOD1= SOD1 G93A genotype, ND= normal diet, HFD=High-fat diet, LDL= low-density
lipoproteins, HDL=High-density lipoproteins, ChAT= Choline o-acetyltransferase, MuSK=Muscle skeletal receptor tyrosine-protein kinase, MuRF1=
Muscle RING-finger protein-1.
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findings in vivo23. The beneficial effects could be due to upre-
gulation of the glucose metabolism92. However, further experi-
ments are needed to elucidate this.
A major problem in the treatment of neurodegenerative dis-
eases is the development of drugs that can cross the BBB. Eto-
moxir is indicated to affect the metabolism both within the CNS93
and in the periphery25. Data presented in the etomoxir
experiments indicate that target engagement takes place both
within the CNS and periphery regarding, e.g., inflammation.
However, another drug that downregulates β-oxidation is rano-
lazine, which has shown beneficial effects by downregulating
CPT1B in the muscles in SOD1 G93A mice50 and inflammation
in vitro94. Therefore, we hypothesize that peripheral target
engagement in SOD1 G93A mice could prove to have effects by
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amelioration of peripheral hypermetabolism and thereby, e.g.,
inflammation and oxidative stress.
In this study, we hypothesized that upregulation of CPT1 by 60%
HFD (based on saturated animal fats) would result in a more severe
disease phenotype. We found that 60% HFD resulted in a more
severe disease phenotype, possibly by increased inflammatory
activity and oxidative stress. The effect of diets on disease progres-
sion in ALS in vivo models have been evaluated previously61.
However, the majority of studies are incomparable because of dif-
ferences in genetic background- and the composition of the HFD.
The studies indicating a positive effect are characterized by diets
containing high amount of unsaturated omega-3 fatty acids61, which
are characterized by anti-inflammatory effects15. Nonetheless, stu-
dies in animal models of other neurodegenerative diseases, e.g.,
multiple sclerosis20 and Parkinson’s-95 and Alzheimer’s disease96
have shown that HFD results in more severe disease progression,
demyelination, inflammation, death of neurons and brain atrophy.
HFD results in upregulation of CPT1and thereby a shift towards
lipid metabolism57. A cross-sectional study found that intake of food
with a traditional high content of saturated fat correlated with a
lower functional ALSFR-R score60. A double-blinded placebo-con-
trolled randomized clinical phase 2 trial found that ALS patients fed
a diet with high fat had more adverse events and deaths compared to
patients receiving a diet with high levels of carbohydrates62. This
indicates that HFD might be undesirable, but larger clinical trials,
and standardized in vivo studies are needed. We also hypothesized
that CORT would exacerbate disease progression in SOD1 mice
because cortisol is increased in several CNS diseases including
ALS73,74 and upregulates β-oxidation70. In accordance with this, we
show that CORT administration for 30 days results in a more severe
disease progression in SOD1 G93A mice based on behavior data. In
addition, our data indicates that CORT resulted in increased levels of
inflammatory cells expressing Cd68. This is in agreement with a
previous study that found a negative correlation between corticos-
terone levels and disease progression in SOD1 G93A mice following
chronic restraint stress76. In addition, chronic upregulation of the
HPA-axis results in increased inflammation76. Nonetheless, further
investigations of the effects of CORT in SOD1 mice are needed.
In the last few years, the role of the gut microbiota in ALS and
in the SOD1 G93A mouse model has received increasing
focus78,80,97. The gut microbiome correlates with multiple disease
mechanisms in SOD1 G93A mice, including inflammation,
muscle pathogenesis and motor neuron pathology80. Accordingly,
the intestinal barrier is disrupted in SOD1 G93A mice resulting in
increased levels gut metabolites and inflammatory cytokines in
the blood, which further can affect both peripheral tissues and the
CNS. Based on this, we hypothesized that downregulation of
CPT1 activity might result in alternations in the gut microbiome
directly and by the change in metabolite levels due to the
downregulated β-oxidation, thereby affecting disease mechanism
in SOD1 G93A mice. We found that downregulation of CPT1 by
etomoxir and CPT1A activity by Cpt1a P479L mutation resulted
in alternations in the fecal gut microbiome including a decrease in
microbiome communities associated with disease. In addition, the
downregulated CPT1A activity resulted in an increase of Lach-
nospiraceae and Odoribacter, which are associated with decreased
muscle atrophy, inflammation and possibly upregulated glucose
metabolism80,86. This point towards that CPT1A activity directly
affects the fecal gut microbiome composition24. In addition, we
hypothesized that 60% HFD and CORT would affect the fecal gut
microbiome directly but also indirectly by the upregulation of
CPT1. HFD and CORT resulted in increased levels of commu-
nities such as Lactobacillus, Streptococcaceae, Desulfovibrionaceae
and a decrease in some OTUs of Lachnospiraceae. These
increased communities are associated with increased production
of inflammatory cytokines within the gut and potentially insulin
resistance due to obesity87,88. This indicates that directly and
indirectly modulation of the gut microbiota by environmental
factors such as diet and stressors could play a role in the dis-
ruption of metabolism and thereby affect multiple mechanism
such as inflammation and metabolism.
In summary, we report that CPT1 lipid metabolism potentially
plays a role in the modulation of disease activity both in the
periphery and within the CNS in the SOD1 G93A mouse model
possibly by regulation of glucose metabolism. This adds to the
increasing knowledge on the interaction between genetic sus-
ceptibility and environment in the development of ALS, and
specifically dysregulated metabolism being a central pathway and
possibly a target for disease modification. Nonetheless, more
mechanistic studies are warranted.
Methods
Animals. All experiments were approved by the Danish Animal Experiment
Inspectorate (2017-15-0202-00088) and followed the National and European
guidelines for conducting animal experiments. Animal experiments was conducted
according to the ARRIVE guidelines. Mice were housed in IVC cages in a high
Fig. 9 Corticosterone accelerates disease progression in the SOD1 G93A mouse model. a Experimental setup, mice were randomized into treatments at
approximately day 70 and tested weekly. 3–4 mice were terminated at day 100 and the rest (3–4) were terminated at day 130. b Time point for onset of
disease defined as visible tremor in hindlimbs (n= 8), log-rank survival analysis. c Neuroscore was assessed once a week. Data are presented as means ±
SEM (n= 8). Mixed effect analysis with Tukey post hoc test. d Hangwire test was performed once a week. Data are presented as mean latency to fall of the
grid ± SEM (n= 8). Mixed effect analysis with Tukey post hoc test. e Grip strength was measured once a week from day 70. Data are presented as means
± SEM (n= 5–8). Mixed effect analysis with Tukey post hoc test. f Mean body weight expressed in grams ± SEM (n= 5–8). Mixed effect analysis with
Tukey post hoc test. g Cylinder test was performed at day 70 and day 100. Data are presented as mean rears ± SEM (n= 5–8). Repeated measure two-way
ANOVA with Tukey post hoc test. h Y-maze test was conducted at day 70 and day 100. Data are presented as mean spontaneous alternation percentage
± SEM (n= 5–8). Paired t-test. i Corticosterone levels in serum obtained at day 100 was analyzed using ELISA. Data are presented as mean ng/mL (n=
3–4). Two-way ANOVA with Tukey post hoc test. j Glucose levels in serum at day 100. Data are expressed as mean mmol/L ± SEM (n= 3–4). Two-way
ANOVA with Tukey post hoc test. k–m Cpt1a, Cd68, and Nox2 gene expression in the lumbar spinal cord from mice terminated at day 130. Data are
presented at mean normalized fold-change. Expression was normalized to β-actin and Gapdh. N= 3–4. Two-way ANOVA with Tukey post hoc test. n–p
Cpt1b, Cd68, and Glut4 gene expression in the tibialis anterior muscle from mice terminated at day 130. Data are presented at mean normalized fold-
change. Expression was normalized to β-actin and Gapdh. N= 3–4. Two-way ANOVA with Tukey post hoc test. Data are representative of two animal
experiments. Serum and RT-qPCR experiment was conducted once. *Significant differences between SOD1+V and SOD1+ CORT, #significant difference
between SOD1 and Wt, $significant differences between Wt+V and Wt+ CORT, % significant differences between SOD1+V and Wt-CORT in body
weight analysis, ¤significant difference between Wt+CORT and SOD1+ CORT in body weight analysis. *p≤ 0.05; **p≤ 0.01; #p≤ 0.05; ##p≤ 0.01, $p≤
0.05, $$p≤ 0.01, % p≤ 0.05, %%p≤ 0.01. WT=wildtype, SOD1= SOD1 G93A genotype, V=Vehicle, CORT= Corticosterone. Mouse figure used in
experimental setup figures were obtained from; https://smart.servier.com/ and used according to the Creative Commons Attribution 3.0 Unsupported
License.
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barrier facility at Aalborg University with a room temperature of 21 °C. The mice
were kept at a 12-hour light/dark cycle and had ad libitum access to food and
water. Sample size was estimated based on previous studies and a pilot study
described in the manuscript.
SOD1 G93A mouse model. B6.Cg-Tg(SOD1*G93A)1Gur/J mice (Stock 004435)
(SOD1) were purchased from Jackson Laboratory (Bar Harbor, USA). The con-
genic SOD1 mice were maintained in our animal facility by crossing hemizygote
SOD1 male mice with female C57Bl/6J mice. Litters were genotyped according to
established protocol using DNA extracted from ear tissue punches80. Male SOD1
mice were used to maintain the colony, and SOD1 female and their wildtype
littermates were used for experiments. All animals were assessed for human end-
points daily, weight twice a week, and neurological score once a week. SOD1 males
(n= 9) and females (n= 5) were evaluated by neurological score, grip strength,
hangwire test and y-maze test at day 140 to evaluate differences between the males
and females as described under clinical behavioral tests. In addition, survival was
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02034-z ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:509 | https://doi.org/10.1038/s42003-021-02034-z | www.nature.com/commsbio 19
evaluated as described under neurological score, onset of disease and survival
analysis.
SOD1 G93AWt/Cpt1a and SOD1 G93ACpt1a/Cpt1a mouse models. B6.Cg-Tg
(SOD1*G93A)1Gur/J male mice were crossed with female B6.Cpt1a P479L
homozygote mice (strain generated in collaboration with the Netherlands Cancer
Institute, Amsterdam, as previously published20 with the use of the genomic Cpt1a
promoter, causing no difference in expression in different tissues) to obtain SOD1
mice with a heterozygote Cpt1a P479L mutation (SOD1 G93AWt/Cpt1a)24. SOD1
G93AWt/Cpt1a mice were crossed with female Cpt1a P479L homozygote mice to
obtain SOD1 G93ACpt1a/Cpt1a. All mice were genotyped using ear punch tissue as
previously described20,80. All animals were assessed for human endpoints daily,
weighted twice a week, and neurological score once a week.
CPT1A antagonist studies. A pilot study was conducted using female SOD1 (n=
10) and wildtype (n= 4) littermates. SOD1 mice were randomized into treatment
with the irreversible CPT1A antagonist, etomoxir (5 mg/kg) (n= 7), or placebo
(olive oil) (n= 3) from day 100. Treatment was administered one a daily basis by
oral gavage. Mice were evaluated weekly by neurological score, weight, and
hangwire test as described under clinical behavior test. Following the pilot study, a
larger study was setup. Female SOD1 (n= 18) and wildtype (n= 9) littermates
were randomized into treatment with etomoxir or placebo from day 70. Mice were
evaluated weekly by neurological score, grip strength, hangwire test, rotarod test,
and at day 70, day 100 and day 130 mice were evaluated by cylinder, and y-maze
test. Moreover, fecal samples were collected at day 70 before treatment start (n=
5), and at day 130 for the two SOD1 treatment groups. Serum, brain, muscle, and
spinal cord tissue was obtained when mice were euthanized between day 145–150.
Another CPT1A antagonist study was conducted from day 70 and until day 130 to
obtain spinal cord tissue for immunohistochemistry. Female SOD1 (n= 11) and
wildtype littermates (n= 4) were randomized into treatment with etomoxir or
placebo and evaluated by neurological score and grip strength once a week, as
described below. At day 130 mice were anesthetized using isoflurane and quickly
perfused with 1xPBS followed by 4% paraformaldehyde and spinal cords were
harvested for further analyzes.
SOD1Wt/Cpt1a and SOD1Cpt1a/Cpt1a studies. SOD1 (n= 5), SOD1Wt/Cpt1a (n= 8),
and SOD1Cpt1a/Cpt1a (n= 10) female mice were evaluated weekly from day 70 by
neurological score, grip strength and hangwire test. Moreover, mice were evaluated
at day 70, 100, and 130 using cylinder (n= 7–11), and y-maze test (n= 6–9). Not
all mice was evaluated by the cylinder and y-maze test, which explains differences
in n. Fecal samples were obtained from SOD1Cpt1a/Cpt1a mice at day 130. For onset
of disease (tremor) evaluation, female SOD1 (n= 15), SOD1Wt/Cpt1a (n= 16), and
SOD1Cpt1a/Cpt1a (n= 12) mice were used. Serum, muscle, and spinal cord tissue
samples were obtained when mice were euthanized between day 145–160. Another
group of female SOD1Wt/Cpt1a (n= 6), SOD1Cpt1a/Cpt1a (n= 3) and SOD1 mice
(n= 4) was evaluated by neurological score from day 70 and until day 132. In
addition, male SOD1Cpt1a/Cpt1a (n= 25) and SOD1 mice (n= 10) was used to
evaluate differences in survival.
SOD1 G93A High-fat diet study. Female SOD1 (n= 14) and their wildtype lit-
termates (n= 10) were randomized into receiving normal diet (kcal% respectively:
protein 29, carbohydrate 65.5, fat 5.5, Brogaarden, Denmark) or high-fat diet (kcal
% respectively: protein 20, carbohydrate 20, fat 60, Brogaarden, Denmark; based on
D12492 research diets, New Brunswick, USA) from day 70. Clinical symptoms
were evaluated weekly by neurological score, grip strength, and hangwire test.
Weight was assessed twice a week. Moreover, mice were evaluated at day 70, and
day 130 using cylinder, and y-maze test. Serum, muscle, and spinal cord tissue
samples were obtained when mice were euthanized between day 145–150.
SOD1 G93A corticosterone study. Female SOD1 (n= 18) and their wildtype
littermates (n= 12) were randomized into receiving vehicle or corticosterone
(20 mg/kg) (Sigma, CAT# 27840) from day 70 and until day 100 by oral gavage as
previously described98. Clinical symptoms were evaluated weekly by neurological
score, grip strength and hangwire test. Weight was assessed twice a week. More-
over, mice were evaluated at day 70, and day 100 using cylinder and y-maze test.
Serum samples were obtained when mice were euthanized at day 100 and day 130,
respectively. Spinal cord and tibialis anterior muscle tissue was harvested at day
130. Fecal samples was obtained from mice at day 130 following 30 days corti-
costerone washout period.
Clinical behavioral tests. All clinical behavioral tests were performed between 9
am and 2 pm. All tests were performed in the same laboratory and mice were
placed in the room one hour before test sessions to allow time for acclimatization.
Test equipment was cleaned with 70% ethanol between each animal.
Neurological score, onset of disease, and survival analysis. Mice were eval-
uated by the same experimenter weekly. The experimenter was blinded to treat-
ment group and genotype. Mice were given a neurological score between zero to
five as previously described30,31. Zero= no tremor in hindlimbs and full extension
of hindlimbs when suspended by its tail. One= tremor in hindlimbs and full
extension of hindlimbs when suspended by its tail. Two= tremor in hindlimbs and
unable to extend hindlimbs when suspended by its tail. Three= tremor in hin-
dlimbs, unable to extend hindlimbs when suspended by its tail and wobbling gait.
Four= tremor in hindlimbs, unable to extend hindlimbs when suspended by its tail
difficulty walking with paralysis of one of both hindlimbs. Five= tremor in hin-
dlimbs, unable to extend hindlimbs and unable to get up within 30 s when placed
on its side. Onset of disease was defined as the time point when tremor in the hind
legs was present as previously described30. Owing to ethical reasons and based on
the guidelines in the Animal Facility, mice were terminated if they reached a
neurological score of four or latest at day 160. Based on this, survival was defined as
a neurological score below 4 at the final day of experimentation. Owing to the fact
that mice had to be terminated at day 160, some mice did not reach a neurological
score of 4 and, therefore, some of the groups have censored data in the survival
analysis.
Hangwire test. Mice were gently placed on a wire grid lid and turn upside down.
The latency to fall was noted. The maximum cutoff time was set to 180 s. Each mice
received three trials per sessions. The highest latency to fall was used for sub-
sequent statistics31.
Rotarod test. Rotarod test (Rotamex-5 RotaRod, Columbus Instruments,
Columbus, Ohio, USA) was used with an acceleration from 4 to 40 RPM over
5 min29. Mice were acclimatized to the rotarod over three consecutive days before
the first test session. Each mouse was tested three times per test session to obtain a
mean latency to fall (s).
Grip strength test. Grip strength was evaluated using Grip strength meter (Bioseb,
France). Briefly, the mouse was placed on a wire grid at pulled by its tail. The
maximum tension was measured in grams Each mouse received four trials at each
session and a mean grip strength was calculated. The mean grip strength was
normalized to weight as previously described24.
Cylinder test. The cylinder test was used to evaluate the sensorimotor function
and spontaneous activity as previously described32. Mice were transferred into a
quiet room with low illumination and placed in the glass cylinders. Test was
recorded for 3 min using a video camera. The number of rears were counted by
four blinded raters.
Y-maze test. The y-maze test was constructed according to Maze Engineers
(USA). The mice were placed in the y-maze for 5 min to freely explore the three
arms. The y-maze test was recorded by video and the number of entries and triplets
Fig. 10 Modulation if CPT1 activity by etomoxir, genetic inhibition, high-fat diet, and corticosterone modulates the gut microbiota in SOD1 G93A mice.
a Heatmap illustrating the ten most abundant communities at the genus level in fecal samples from SOD1 mice and Wt mice at day 70. Values represents
mean relative abundancy. b Heatmap illustrating the ten most abundant communities at the genus level in fecal samples from SOD1 mice at day 70, day
130, and Wt mice at day 130. Values represents mean relative abundancy. c Heatmap illustrating the ten most abundant communities at the genus level in
fecal samples from SOD1+ P, SOD1+ E, and Wt mice at day 130. Values represents mean relative abundancy. d Heatmap illustrating the ten most
abundant communities at the genus level in fecal samples from SOD1 and SOD1Cpt1a/Cpt1a mice at day 130. Values represents mean relative abundancy.
e Heatmap illustrating the ten most abundant communities at the genus level in fecal samples from SOD1+ND, SOD1+HFD, Wt+ND, and Wt+HFD
mice at day 130. Values represents mean relative abundancy. f Heatmap illustrating the ten most abundant communities at the genus level in fecal samples
from SOD1, SOD1+ CORT, Wt, and Wt+CORT mice at day 130. Values represents mean relative abundancy. Fecal pellet samples were harvested at day
70 or day 130, n= 4–5. Data are representative of one 16S rRNA sequencing experiment. Wt=wildtype, SOD1= SOD1 G93A genotype, SOD1Cpt1a/Cpt1a=
SOD1 G93A mice with homozygote Cpt1a p479l mutation. E= etomoxir, P= placebo, HFD= high-fat diet, CORT= corticosterone.
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were noted by four blinded raters as previously described99. The mean spontaneous
alternation percentage was calculated as previously described99.
Serum glucose-, low-density lipoprotein cholesterol-, and high-density lipo-
protein cholesterol assays. Blood samples were obtained from mice by retro
orbital puncture. Mice were in fed-state. Samples were placed at room temperature
for 40 min and afterwards samples were centrifuged at 3500 × g for 15 min and the
supernatant was transferred and stored at −80 °C until further analyses. Serum
analyses of glucose- (Crystal Chem, CAT#81692), low-density lipoprotein choles-
terol (LDL) (Crystal Chem, CAT#79980), high-density lipoprotein cholesterol
(HDL) (Crystal Chem, CAT#79990) and corticosterone (Crystal Chem,
CAT#80556) levels were performed using commercial assay kits according to the
manufactures instructions. Samples- and standards were run in duplicates and
were analyzed using a plate reader (PerkinElmer). Concentrations were obtained,
based on standard curve methods as described in the manufacture’s protocols.
Reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR).
RNA was extracted from brain, spinal cord and tibialis anterior muscle using
GeneJET RNA purification kit (ThermoFisher, CAT# K0732). Following RNA
extraction, quality and quantity was evaluated using NanoDrop. cDNA synthesis
and qPCR was performed as previously described20. All samples were run in
duplicates. The following primers RT² qPCR Primer Assay for Mouse were pur-
chased from Qiagen: Igf1 (PPM03387F-200), Mbp (PPM04745F), Chrna1
(PPM03976A), Cpt1b (PPM57688A), Casp1 (PPM02921E), Cd68 (PPM03976A).
The following primers were purchased from TagCopenhagen (Denmark): Cpt1a
rev: GGAGGTTGTCCACGAGCCAG, fwd: TCATCAGCAACCGGCCCAAA.
Cpt1c rev: TTTTCCAGGAGCGCAGGG, fwd: CTGACCTCTGACCGGTGGGC.
Nrf2 rev: GGGGATATCCAGGGCAAGCG), fwd: CGCCAGCTACTCCCAGG
TTG. Il-17a rev: GTCCAGCTTTCCCTCCGCAT, fwd: CCTGGACTCTCCACC
GCAATG. Ifn-ϒ rev: CTTCCCCACCCCGAATCAGC, fwd: GCCAAGTTTG
AGGTCAACAACCC. β-actin rev: TCGTCATCCATGGCGAACTGG, fwd: CT
GTCGAGTCGCGTCCACC. Ho1 rev: ATCCTGGGGCATGCTGTCGG, fwd:
GAGCCGTCTCGAGCATAGCC. Nox2 rev: TTCAGCCAAGGCTTCAGGGC,
fwd: TGGACGGCCCAACTGGGATA. Pgc1α rev: TGCGGTATTCATCCC
TCTTG, fwd: CACCGCAATTCTCCCTTGTA. Hprt rev: CGCTAATCACGA
CGCTGGGA, fwd: GGGAGAGCGTTGGGCTTACC. Slc2a4 (Glut4) rev:
CCTCCCGCCCTT AGTTG, fwd: CTGCAA AGC GTA GGT ACC AA. Gapdh rev:
TGTGAGGGAGATGCTCAGTG, fwd: GTGGAC CTCATGGCCTACAT. Apoe
rev: TGT GTG ACT TGG GAG CTC TG, fwd: GTGCTGTTGGTCACATTGCT.
Iba1 rev: AGTTGGCTTCTGGTGTTCTTTGTTT, fwd: GTTCCCAAGACCCA
TCTAGAGCTG. Gfap rev: CAGGGCTCCATTTTCAATC, fwd: ACAGACT
TTCTCCAACCTCCA. Chat rev: GGATGGGAGCAGGGTTAGTA, fwd: CACC
AACAGCAAAGGAAAGA. Gene expression in spinal cord- and tibialis anterior
tissue was normalized to Gapdh and β–actin. Gene expression in brain tissue
(Supplementary Fig. 3) was normalized to Hprt and β–actin. Mean fold-change
expression was calculated according to 2–ΔΔCt method.
Immunohistochemistry. Immunohistochemical peroxidase staining on the lumbar
spinal cord was performed to evaluate morphological changes between genotypes
and treatment groups. Tissue was processed as previously described20,23. The fol-
lowing primary antibodies were used: MBP 1:800 (Abcam, CAT# ab7349), GFAP
1:1000 (Agilent, CAT# Z033429-02), CPT1A 1:400 (ThermoFisher Scientific,
CAT# PA5-69347), IBA-1 1:500 (Wako, CAT#013-27691), CHAT 1:400 (Merck
Millipore, CAT#ab144p). The following secondary HRP-conjugated antibodies
were used: Goat Anti-rat 1:500 (ThermoFisher Scientific, CAT# PA1-84708), and
Goat Anti-rabbit 1:500 (Dako, CAT# P0448). The sections were imaged using a
Leica microscope as previously described23. All microscopy settings were kept
identical during the entire acquisition process.
Enzyme-linked immunosorbent assay (ELISA). Spinal cord tissue and muscle
tissue were weighted and quickly homogenized in ice cold PBS according to
manufactures protocols followed by centrifugation at 4500 × g for 5 min at 4 °C.
The supernatant was transferred and used in the subsequent ELISA experiments.
The following commercial ELISA kits were used CHAT (Biosite, CAT#EXX-
74AG9R-96), CX3CR1 (Biosite, CAT#EXX-FR3AVA-96), IL-10 (Invitrogen, CAT#
88-7105-22), IL-1β (Invitrogen, CAT# 88-7013-22), TNF-α (Invitrogen, CAT# 88-
7324-86), MuSK (Aviva systems biology, CAT#OKEH07075), MuRF1 (Biosite,
CAT#EXX-ARLE1G-96), Atrogin-1 (FBXO32) (Biosite, CAT#EKK-6W410X-96),
Myogenin (Aviva systems biology, CAT#OKEH03290). Serum was obtained as
described above, diluted 1:100 in commercial included buffer and used in the
mouse NF-L ELISA kit (LSBio, CAT#LS-F70035). All samples were run in dupli-
cates. All procedures were done according to the manufactures protocols. ELISAs’
were read at 450 nm using a plate reader (PerkinElmer). Concentrations were
obtained based on standard curve methods, as described in the manufactures’
protocols. Following, concentrations were normalized to total protein concentra-
tion in the respective samples. Total protein concentrations were estimated using
Nanodrop technology.
Fecal gut 16S rRNA microbiome analyses. Fecal pellets were stored at minus 80 °
C until further analyzes. DNA was extracted from fecal pellets using Quick-DNA
Fecal/Soil Microbe Miniprep Kit (Zymogene, CAT# D6010) according to the
manufacture’s protocol. Quantity and quality of extracted DNA was assessed using
Nanodrop. Following extraction, DNA was handed over to DNASense Aps (Aal-
borg, Denmark) for 16s rRNA V4 region sequencing and bioinformatics proces-
sing. Library preparation-, sequencing and bioinformatics were done as previously
published24. Heapmaps, principal component analysis and DESeq2 with
Benjamin–Hochberg adjustment analysis were conducted using https://dnasense.
shinyapps.io/dnasense/ provided by DNASense ApS (Aalborg, Denmark) based on
the ampvis R package described in ref. 24.
Statistics and reproducibility. All statistics was performed using Graphpad Prism
v. 8.0 except for the 16s rRNA microbiome analyzes. Normality and variance was
evaluated before performing statistical analysis. Pairwise comparison were gener-
ated with two-tailed paired t-test. Independent groups were compared using two-
tailed unpaired t-test. Comparison of more than two independent groups was
performed by one-way ANOVA followed by Tukey multiple comparison test. Two-
way ANOVA followed by Tukey multiple comparison test was performed when
more than three groups were compared with two factors. Repeated measure two-
way ANOVA were conducted when several groups were tested multiple times
followed by post hoc Bonferroni or Tukey multiple comparison test. Survival
analysis was done by log-rank test. Outliers were evaluated by Grubbs method. P-
values, n-values, definition of center and dispersion measurements are indicated in
the associated figure legends for each figure. Number of repeated experiments are
described in the figure legends. Repeated experiments produced comparable results
and findings were considered reproducible.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data for the microbiome studies are freely available from Mendeley Data using
https://doi.org/10.17632/6zt29bjbzd.1. Source data for figures are available in
Supplementary Data 2. In addition, data that support the findings of this study are
available from the corresponding author (J.D.V.N) upon reasonable request.
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